Anita ChandraAnita is a medic who obtained her primary medical degree from the University of Cambridge in 1998. Following general medical training where she obtained membership of the Royal College of Physicians (MRCP), she commenced her training in Clinical Immunology, initially in Newcastle upon Tyne and soon thereafter, at Addenbrooke’s hospital in Cambridge. She subsequently obtained her Fellowship of the Royal College of Pathologists (FRCPath) and currently works as an Honorary Consultant at Addenbrooke’s hospital in Clinical Immunology. Her clinical interests involve the management and care of patients with primary and secondary immunodeficiency.
Anita obtained her PhD from the University of Cambridge following work on B cell biology and antibody diversification in the Laboratory of Molecular Biology under the supervision of Professor Michael Neuberger and Dr Cristina Rada. She is currently working as a Wellcome Trust funded Postdoctoral Clinical Fellow in the Okkenhaug lab, focusing on the role of PI3Ks in human and murine immunity and susceptibility to infections. She has a particular interest in a group of patients with an activating mutation in PI3K delta (APDS) and will be complementing basic mechanistic research in this area with clinical trials using selective PI3K delta inhibitors in patients.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Okkenhaug K, Graupera M, Vanhaesebroeck B
Eil R, Vodnala SK, Clever D
537 1476-4687:539-543 (2016)
Lucas CL, Chandra A, Nejentsev S
Nature reviews. Immunology
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM
The Journal of allergy and clinical immunology
Roychoudhuri R, Clever D, Li P
Inhibition of Phosphoinositide 3-Kinase p110delta Does Not Affect T Cell Driven Development of Type 1 Diabetes Despite Significant Effects on Cytokine Production.
Barbera Betancourt A, Emery JL, Recino A
11 1932-6203:e0146516 (2016)
PI3Kδ promotes CD4(+) T cell interactions with antigen presenting cells by increasing LFA-1 binding to ICAM-1.
Garçon F, Okkenhaug K
Immunology and cell biology
Roychoudhuri R, Eil RL, Clever D
The Journal of clinical investigation
Okkenhaug K, Roychoudhuri R
8 1937-9145:pe3 (2015)
Okkenhaug K, Burger JA
Current topics in microbiology and immunology
393 0070-217X:123-42 (2016)
Sauer K, Okkenhaug K
Frontiers in immunology
6 1664-3224:410 (2015)
Pearce VQ, Bouabe H, MacQueen AR
Journal of immunology (Baltimore, Md. : 1950)